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Background: The guidelines on trigeminal neuralgia management that have been agreed and jointly published by the
American Academy of Neurology and the European Federation of Neurological Societies recommend carbamazepine (CBZ)
and oxcarbazepine (OXC) as the first-choice medical treatments in patients with trigeminal neuralgia (TN). The aim of this retro-
spective study was to analyze the natural history of classical trigeminal neuralgia in a large cohort of patients, focusing on drug
responsiveness, side effects related to CBZ and OXC, and changes in pain characteristics during the course of disease.
Findings:We selected the last 100 consecutive patients with typical TN who began treatment with CBZ and the last
100 with OXC. All had MRI scans and a complete neurophysiological study of trigeminal reflexes. Among them, 22
were excluded on the basis of neuroradiological or neurophysiological investigations, to avoid the inclusion of patients
with possible secondary TN. The initial number of responders was 98% with CBZ with a median dose of 600 mg (range
200–1200), and of 94% with OXC, with a median dose of 1200 mg (range 600–1800). In a mean period of 8.6 months,
27% of responders to CBZ incurred in undesired effects to a level that caused interruption of treatment or a dosage
reduction to an unsatisfactory level. In a mean period of 13 months, the same occurred to 18% of responders to OXC.
Among patients who had a good initial response, only 3 patients with CBZ and 2 with OXC developed late resistance.
During the course of disease, paroxysms worsened in intensity in 3% of patients, and paroxysms duration increased in
2%. We did not observe the onset of a clinically manifest sensory deficit at any time in any patient.
Conclusions: Unlike common notion, in our large patient sample the worsening of pain with time and the
development of late resistance only occurred in a very small minority of patients. CBZ and OXC were confirmed to be
efficacious in a large majority of patients, but the side effects caused withdrawal from treatment in an important
percentage of patients. These results suggest the opportunity to develop a better tolerated drug.
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Trigeminal Neuralgia (TN) is a clinical condition charac-
terized by a sudden, usually unilateral, brief, stabbing,
recurrent pain with a distribution consistent with one or
more divisions of the fifth cranial nerve [1]. The paroxys-
mal attacks are stereotyped in the individual patient, last
from a fraction of a second to 2 minutes [2] and may be
evoked by stimulating cutaneous or mucous trigeminal* Correspondence: cruccu@uniroma1.it
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in any medium, provided the original work is pterritories, the so-called trigger zones. The pain-free inter-
vals may range from days to years [3]. TN may be distin-
guished in classical, namely without a cause other than a
neurovascular compression, or secondary to a demonstrable
lesion, including benign tumors of the cerebellopontine
angle or multiple sclerosis [4-6]. According to the symptom
constellation, TN is categorized into typical and atypical
form, the latter characterized by a constant and non-
lancinating background pain and, sometimes, sensory
disturbances in the affected division [7,8]. The annualis an Open Access article distributed under the terms of the Creative Commons
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men [9].
According to the American Academy of Neurology
(AAN), the European Federation of Neurological Societies
(EFNS) and also other recent guidelines, carbamazepine
(CBZ) and oxcarbazepine (OXC) are the first-line medical
treatments for pain control in patients with TN [10-12].
They have the same mechanism of action, namely the
blockade of voltage-gated sodium channels in a frequency-
dependent manner. OXC may be preferred because of the
minor risk for drug interactions and its better tolerability
in comparison with CBZ [11]. The AAN-EFNS guidelines
recommended that patients unresponsive or that cannot
reach the therapeutic dosage of the drug because of
adverse events should be made aware of the availability of
surgery. Surgical procedures include Gasserian ganglion
percutaneous techniques, microvascular decompression in
the posterior fossa, and gamma knife radiosurgery. These
procedures are extremely efficacious with relatively few
complications. Microvascular decompression may be
considered over other surgical techniques to provide the
longest duration of pain freedom [10]. According to the
available evidence no oral treatment is better than CBZ or
OXC, but in case of refractory trigeminal neuralgia, among
the non-surgical option, lamotrigine and botulinum toxin
injections should be considered [13].
Up to now, only few studies have focused on the devel-
opment of the clinical picture and the drug efficacy and
tolerability in time. The aim of this retrospective study
was to analyze the natural history of TN in a large cohort
of patients, by focusing on the drug responsiveness, the
side effects related to the pharmacological treatment, the
changes in pain characteristics along with the duration of
the disease, such as duration and intensity of paroxysms,
and the possible onset of sensory disturbances.
Methods
The staff nurse retrospectively selected the clinical notes
of outpatients with a diagnosis of classical TN who had
attended our centre for neuropathic pain from January
2000 to June 2013. One of us analyzed the clinical notes
and selected the last consecutive 100 patients who began
treatment with CBZ and the last consecutive 100 who
did it with OXC. All patients included in the analysis
suffered from paroxysmal attacks of pain lasting from a
fraction of a second to 2 minutes, affecting one or more
divisions of the trigeminal nerve. Pain was described as
intense, sharp, superficial or stabbing; paroxysms could
be both spontaneous and precipitated from trigger areas
or by trigger factors. The attacks were stereotyped in the
individual patient. The clinical examination did not
show any clinical neurological deficit [2]. All patients
had undergone MRI scans of the brain and trigeminal
reflex testing [4,6,10] in order to identify with certaintyeven patients with typical presentation but a possibly
secondary origin, including idiopathic sensory trigeminal
neuropathy and nerve trauma [14].
Patients were seen at least monthly until the target
dosage and/or a significant pain reduction was reached.
Then, follow-up visits were scheduled every six months,
unless side effects occurred.
Two staff members were involved in the clinical exam-
ination and two in the neurophysiological testing. The
diagnosis of classical trigeminal neuralgia was confirmed
by at least two clinicians.
We focused our attention on the average onset age of
TN, the number of responders to CBZ or OXC, the pos-
sible CBZ/OXC lost efficacy, the side effects that caused
interruption of treatment or a dosage reduction to an un-
satisfactory level and the latency for the side effect onset.
Patients were considered as responders on the bases of
their global satisfaction and the willingness to continue
the drug.
We also analyzed the possible change in pain character-
istics during the course of disease, including paroxysms
duration and intensity. By definition, classical TN is a pain
syndrome that arises without a clinically manifest sensory
deficit: anyway, we wanted to test the likelihood of the
onset of sensory disturbances during the disease course.
Findings
We considered an otherwise homogeneous group of 200
patients (68 M, 132 F, mean age 67.54 ± 12.11), with a
mean follow-up period of 7.31 years. Among them, 22 pa-
tients with typical symptom constellation and a diagnosis
of classical TN were excluded from the study because two
of us considered the results of neurophysiological or neu-
roimaging investigations insufficient to exclude a second-
ary form with absolute certainty. The other 178 patients
had a classical TN, without any evidence of a cause other
than a neurovascular conflict at dedicated MRI scans.
Ninety-five out of 178 patients were treated with CBZ and
the remaining 83 with OXC. The average onset age of
symptoms was 60 ± 11.6 years (range 35-80).
The initial number of responders was 98% with CBZ
at a median dosage of 600 mg (range 200–1200 mg),
and of 94% with OXC at a median dosage of 1200 mg
(range 600–1800 mg). Among responders to CBZ, 27%
of patients incurred in adverse events that directly
caused interruption of treatment by the physician or a
dosage reduction to a level that was insufficient to con-
trol pain, thus causing discontinuation, after a mean
period of 8.6 months. In a mean period of 13 months,
physician- or patient-decided discontinuations occurred
in 18% of patients initially responders to OXC.
The causes of these discontinuations are plotted in
Figure 1. The CNS disturbances were about triple in
patients on CBZ than those on OXC. In detail, the CNS
Figure 1 Tolerability of Carbamazepine (CBZ) and Oxcarbazepine
(OXC). Y-axis: number of patients that discontinued first treatment
because of adverse events. X-axis: causes of discontinuation. Note that
CNS disturbances affected far more frequently the patients on CBZ,
whereas hyponatremia only affected patients on OXC. The sum of
patients reporting somnolence, postural unbalance, and dizziness is
higher than the total CNS disturbances because many patients
complained of more than one CNS disturbance.
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with CBZ and 5 with OXC), postural unbalance (6 with
CBZ and 4 with OXC) and dizziness (6 with CBZ and 1
with OXC). Among patients under CBZ, three had an
increase of transaminases, one anemia, one leucopenia,
and one thrombocytopenia. Among those under OXC, 5had hyponatremia, one patient had thrombocytopenia.
Allergic reactions (cutaneous rash) affected two patients
on CBZ and two on OXC.
The onset of side effects on the CNS occurred with a
mean dosage of 600 mg for CBZ and 1200 mg for OXC.
With CBZ, anaemia, leucopenia, and thrombocytopenia
occurred within the first three weeks of treatment, with
dosages of 600 mg, 600 mg, and 1000 mg, respectively.
With OXC, thrombocytopenia occurred within the first
two weeks of treatment, with a dosage of 1200 mg. Hypo-
natremia was observed within the first month, with
dosages of 900 mg in one patient, 1200 mg in three
patients and 1800 mg in the fifth patient. Allergic reac-
tions occurred at the beginning of treatment, i.e. within
the first two days. In this case the treatment was inter-
rupted immediately. Among patients that had to interrupt
CBZ because of adverse events, 16 were switched to OXC,
and 5 to gabapentin. The new treatment was effective in
12 patients (10 with OXC and 2 with gabapentin), whereas
in 7 patients (6 with OXC and 1 with gabapentin) the new
treatment was unsuccessful. The remaining two patients
were lost to follow up. Among patients that had to inter-
rupt OXC because of adverse events, 3 were switched to
CBZ, and 2 to gabapentin. The new treatment was effect-
ive in 4 patients (3 with CBZ and 1 with gabapentin),
whereas in the remaining patient the new treatment was
unsuccessful. Eight patients were lost to follow up. Even-
tually, 13 patients out of 178 were referred for surgery (5
patients treated with OXC and 8 with CBZ). Among
patients who had a good initial response, three patients
with CBZ and two with OXC developed late resistance
after 24–76 months. The intensity of paroxysms worsened
in six patients and their duration in four. Such a worsening
occurred in a mean time of 55 months. Constant pain
developed in 5 patients, after an average duration of
disease of 7 years. We did not observe the development of
sensory disturbances with time in any patient suffering
from classical TN.Discussion
In this retrospective study in a large cohort of patients,
we investigated the natural history of classical TN, fo-
cusing our attention on the efficacy of CBZ or OXC, the
possible onset of a late resistance and the side effects
that eventually caused either interruption of treatment
or a dosage reduction to an unsatisfactory level. The
possible modifications in pain characteristics during the
course of disease, including paroxysms duration and in-
tensity, were also examined.
We found that the worsening of pain with time and the
development of late resistance only occurred in a very
small minority of patients. CBZ and OXC were confirmed
to be efficacious in a large majority of patients, but the
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important percentage of patients.
Demographics matched those observed in previous
studies [9], with a higher frequency in women (65.17%)
and an average onset age at 60 years.
We found changes in pain characteristics only in an ex-
tremely small sub-set of patients, compared to the total
number. Such changes included the increase of both par-
oxysms duration and intensity. Unlike other reports [15],
no sensory deficit was observed since the beginning of the
disease.
It is generally agreed that the first line therapy of TN is
pharmacological and based on the use of sodium channels
blockers, CBZ and OXC. Four placebo-controlled trials
demonstrated the efficacy of CBZ [16-19] with a number
needed to treat to obtain important pain relief of 1.7-1.8
[20]. This efficacy is however compromised by the toler-
ability, with a numbers needed to harm of 3.4 for minor
and of 24 for severe adverse events [21,22]. OXC has a
comparable efficacy to that of CBZ but a greater tolerabil-
ity and a lower potential for drug interaction [23-25].
This study confirmed that CBZ and OXC are efficacious
in a great majority of patients and that OXC is more toler-
ated in comparison with CBZ. If compared with other
reports, the percentage of non responders was somewhat
lower in our sample. Because CBZ and OXC are extremely
efficacious in increasing the refractory period of action po-
tentials, they are bound to be most active on the high-
frequency discharges that characterize the paroxysms of tri-
geminal neuralgia. Naturally, if the patient selection is not
very strict, and concedes the recruitment of a few patients
that also have some ongoing pain, then the efficacy of CBZ/
OXC may drop. Indeed, the diagnostic accuracy has always
been a problem in studies in trigeminal neuralgia.
Adverse events may cause withdrawal from treatment.
This occurred in a significant amount of patients, 27% of
those with CBZ and 18% of those with OXC, who were
initially responders. The most frequent adverse effects
involved the central nervous system, and included somno-
lence, dizziness and postural unbalance. CBZ had a higher
percentage of discontinuations for all kinds of side effect,
except for sodium depletion, which only occurred with
OXC (Figure 1).
Although in our centre we are well aware of the great ef-
ficacy of surgical interventions for trigeminal neuralgia
[10,11] and we always offer this chance to patients resist-
ant to CBZ/OXC, only 7% of this large cohort of patients
was eventually sent for surgery, a proportion decidedly
low if compared to those reported by neurosurgical cen-
tres. To explain the low proportion of patients sent for
surgery, we may think of this main explanation: the local
population is not so keen on undergoing surgery unless
they really cannot manage with medical treatment and the
number of patients resistant to CBZ/OXC was very low.In conclusion, the failure of the treatment with CBZ/
OXC, most of the times, is not due to the inefficacy of the
drug, but rather to undesired effects to a level that causes
interruption of treatment or a dosage reduction to an
insufficient level. These results suggest the opportunity to
develop a better tolerated drug.
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